Skip to main content
. 2016 Mar 31;3(3):177–188. doi: 10.1002/ehf2.12088

Figure 2.

Figure 2

Tolvaptan preserved renal functions and decreased blood urea nitrogen/Cr ratio. Changes between baseline and intensive treatment end in serum Cr (A) and eGFR (B). (C) WRF incidence during intensive treatment. (D) Increase in serum Cr to gain 1000 mL of urine volume during intensive treatment. Changes between baseline and intensive treatment end in blood urea nitrogen (E) and blood urea nitrogen/Cr ratio (F). *P < 0.05, **P < 0.01 vs. furosemide. TLV indicates tolvaptan; WRF, worsening renal function.